Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
Status:
RECRUITING
Trial end date:
2029-04-17
Target enrollment:
Participant gender:
Summary
This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.
Phase:
PHASE2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.